Literature DB >> 36085537

Lysosomal Pathogenesis of Parkinson's Disease: Insights From LRRK2 and GBA1 Rodent Models.

Mattia Volta1.   

Abstract

The discovery of mutations in LRRK2 and GBA1 that are linked to Parkinson's disease provided further evidence that autophagy and lysosome pathways are likely implicated in the pathogenic process. Their protein products are important regulators of lysosome function. LRRK2 has kinase-dependent effects on lysosome activity, autophagic efficacy and lysosomal Ca2+ signaling. Glucocerebrosidase (encoded by GBA1) is a hydrolytic enzyme contained in the lysosomes and contributes to the degradation of alpha-synuclein. PD-related mutations in LRRK2 and GBA1 slow the degradation of alpha-synuclein, thus directly implicating the dysfunction of the process in the neuropathology of Parkinson's disease. The development of genetic rodent models of LRRK2 and GBA1 provided hopes of obtaining reliable preclinical models in which to study pathogenic processes and perform drug validation studies. Here, I will review the extensive characterization of these models, their impact on understanding lysosome alterations in the course of Parkinson's disease and what novel insights have been obtained. In addition, I will discuss how these models fare with respect to the features of a "gold standard" animal models and what could be attempted in future studies to exploit LRRK2 and GBA1 rodent models in the fight against Parkinson's disease.
© 2022. The Author(s).

Entities:  

Keywords:  Animal models; Glucocerebrosidase; LRRK2; Lysosomes; Neuropathology; Parkinson’s disease

Year:  2022        PMID: 36085537     DOI: 10.1007/s13311-022-01290-z

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   6.088


  122 in total

Review 1.  Insights from late-onset familial parkinsonism on the pathogenesis of idiopathic Parkinson's disease.

Authors:  Mattia Volta; Austen J Milnerwood; Matthew J Farrer
Journal:  Lancet Neurol       Date:  2015-10       Impact factor: 44.182

Review 2.  Genetics of Parkinson's disease.

Authors:  Christine Klein; Ana Westenberger
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

Review 3.  Genetics of Parkinson disease: paradigm shifts and future prospects.

Authors:  Matthew James Farrer
Journal:  Nat Rev Genet       Date:  2006-04       Impact factor: 53.242

Review 4.  The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins?

Authors:  Donato A Di Monte
Journal:  Lancet Neurol       Date:  2003-09       Impact factor: 44.182

5.  Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.

Authors:  M H Polymeropoulos; C Lavedan; E Leroy; S E Ide; A Dehejia; A Dutra; B Pike; H Root; J Rubenstein; R Boyer; E S Stenroos; S Chandrasekharappa; A Athanassiadou; T Papapetropoulos; W G Johnson; A M Lazzarini; R C Duvoisin; G Di Iorio; L I Golbe; R L Nussbaum
Journal:  Science       Date:  1997-06-27       Impact factor: 47.728

Review 6.  Parkinson disease.

Authors:  Werner Poewe; Klaus Seppi; Caroline M Tanner; Glenda M Halliday; Patrik Brundin; Jens Volkmann; Anette-Eleonore Schrag; Anthony E Lang
Journal:  Nat Rev Dis Primers       Date:  2017-03-23       Impact factor: 52.329

7.  Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis.

Authors:  J W Langston; P Ballard; J W Tetrud; I Irwin
Journal:  Science       Date:  1983-02-25       Impact factor: 47.728

8.  MPTP-induced parkinsonism in human and non-human primates--clinical and experimental aspects.

Authors:  J W Langston; E B Langston; I Irwin
Journal:  Acta Neurol Scand Suppl       Date:  1984

9.  100 years of Lewy pathology.

Authors:  Michel Goedert; Maria Grazia Spillantini; Kelly Del Tredici; Heiko Braak
Journal:  Nat Rev Neurol       Date:  2012-11-27       Impact factor: 42.937

Review 10.  Vesicular Dysfunction and the Pathogenesis of Parkinson's Disease: Clues From Genetic Studies.

Authors:  Kirsten Ebanks; Patrick A Lewis; Rina Bandopadhyay
Journal:  Front Neurosci       Date:  2020-01-08       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.